Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland

@article{Chancellor2012EconomicEO,
  title={Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland},
  author={J. Chancellor and E. Hunsche and Edith de Cruz and F. Sarasin},
  journal={PharmacoEconomics},
  year={2012},
  volume={19},
  pages={59-75}
}
AbstractObjective: The aim of this study was to predict the cost effectiveness of celecoxib, a cyclo-oxygenase 2 (COX-2) specific inhibitor, in the treatment of arthritis patients in Switzerland. Methods: We applied a decision analytical model to compare the effects of 6 months’ treatment with the following: (i) celecoxib; (ii) nonsteroidal anti-inflammatory drug (NSAID) alone; NSAID protected with (iii) proton pump inhibitor (PPI), (iv) histamine H2 receptor antagonist (H2RA), or (v… Expand
The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia
TLDR
Celecoxib with/without PPI co-therapy was deemed very cost effective for medium- and long-term use in Saudi Arabian OA patients aged ≥65 years and showed a significantly higher likelihood that celecoxib plus PPI and cele Coxib alone would be more cost effective versus comparators once the willingness to pay is over US$ 2,000.00. Expand
Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
TLDR
The model suggests, with its underlying assumptions and data, that etoricoxib is a cost-effective alternative to therapeutic regimens involving non-selective NSAIDs for OA or RA, from the UK NHS perspective. Expand
Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis
TLDR
For patients with OAaged >65 years in whom paracetamol therapy has failed, rofecoxib may represent a cost-effective alternative to nonselective NSAIDs and offer increased benefit among patients at a higher risk of serious gastrointestinal events. Expand
Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?
TLDR
Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Expand
Modelling Therapeutic Strategies in the Treatment of Osteoarthritis
TLDR
Meloxicam was predicted to be the lowest cost drug therapy and thus the optimal drug therapy, in the management of patients with osteoarthritis compared with nonselective NSAIDs such as diclofenac and piroxicam in the 4-week trials. Expand
COST-EFFECTIVENESS OF GLUCOSAMINE, CHONDROITIN SULFATE, THEIR COMBINATION, CELECOXIB, NON-SELECTIVE NON- STEROIDAL ANTI-INFLAMMATORY DRUGS, AND PLACEBO IN TREATING KNEE OSTEOARTHRITIS
TLDR
The costeffectiveness of conventional medicines such as non-steroidal anti-inflammatory drugs (NSAIDs) and celecoxib and complementary and alternative medicines (CAM) therapies to treat KOA is examined from the US health care payers’ and patients’ perspectives and from 24week, 2-year, and 10-year time-horizons. Expand
Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
TLDR
Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs, as well as overviewing its pharmacological properties. Expand
Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies
TLDR
Overall, based on local standards, economic models indicated favorable cost–effectiveness profiles for celecoxib compared with nonselective NSAIDs and other active-treatment options. Expand
Anális is co s te -e fe ctividad de l e mple o de ce le co xib e n e l tratamie nto de la artro s is
TLDR
Celecoxib can be considered as a cost-effective option in the treatment of osteoarthritis because its use prevents deaths and increases survival rate and the additional cost is reasonable and moderate compared with that of NSAIDs. Expand
Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective
TLDR
It is estimated that duloxetine was potentially cost effective in the base-case population and more cost effective for subgroups over 65 years or at high risk of NSAID-related AEs. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 28 REFERENCES
A Framework for Evaluating the Clinical Consequences of Initial Therapy with NSAIDs, NSAIDs plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis
TLDR
Clinical probabilities indicate celecoxib has significant tolerability and safety advantages compared with nonselective NSAIDs, and reduces the risk of GI adverse events to a similar or superior degree when compared with reductions observed with NSAIDs with concomitant GPAs. Expand
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
TLDR
COX-2 inhibition with celecoxib is an effective approach for the treatment of osteoarthritis, as seen by clinical improvement in signs and symptoms comparable to treatment with naproxen. Expand
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
TLDR
All dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen. Expand
Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity
TLDR
The cost of treating the gastrointestinal (GI) events associated with the use of nonsteroidal anti-inflammatory drugs in patients with osteoarthritis and rheumatoid arthritis differs significantly across countries as a result of variations in resources consumed and price/tariff policies. Expand
Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.
TLDR
Knowledge of the risk factors for NSAID-associated gastropathy and their inter-relationships provides a tool for identification of the patient at high risk and for initiation of appropriate therapeutic action. Expand
Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs.
TLDR
It was showed that nizatidine, 150 mg, twice daily, significantly reduces the incidence of ulcer formation in high-risk patients taking long-term NSAID therapy, and also relieves NSAID-associated dyspeptic symptoms in some patients. Expand
Misoprostol in the prevention of NSAID-induced gastric ulcer: a multicenter, double-blind, placebo-controlled trial.
  • S. Roth
  • Medicine
  • The Journal of rheumatology. Supplement
  • 1990
TLDR
Mild-to-moderate, self-limiting diarrhea was the most frequently reported adverse event attributed to misoprostol use, and a statistically significant difference persisted when comparisons were restricted to development of ulcer greater than 0.3 cm in diameter. Expand
The Burden of Arthritis and Nonsteroidal Anti-Inflammatory Treatment
TLDR
The review shows that, as well as having a significant impact on healthcare budgets, arthritis also affects patients and caregivers, and it was found that the iatrogenic costs related to the treatment of NSAID-induced adverse events are a significant component of the total costs of arthritis. Expand
PREVENTION OF NSAID-INDUCED GASTRIC ULCER WITH MISOPROSTOL: MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
TLDR
Results provide the first clear indication that NSAID-induced ulcers are preventable, and Mild to moderate, self-limiting diarrhoea was the most frequently reported adverse effect attributed to misoprostol. Expand
Misoprostol Dosage in the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Gastric and Duodenal Ulcers: A Comparison of Three Regimens
TLDR
The effectiveness and tolerability of three different misoprostol regimens were determined, which were shown to provide significant protection against NSAID-induced gastric and duodenal ulcers and to reduce the incidence of ulcer complications. Expand
...
1
2
3
...